Sol-Gel acquires Gorlin syndrome drug candidate Patidegib from PellePharm

Sol-Gel Technologies, an Israel-based dermatology company, has acquired patidegib, a Gorlin syndrome drug candidate in phase 3 development, from US-based biotechnology company PellePharm, in a ... Read More